Journal article
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer
Gynecologic oncology reports, Vol.46, pp.101156-101156
04/01/2023
DOI: 10.1016/j.gore.2023.101156
PMCID: PMC9995928
PMID: 36910448
Abstract
•
The Khorana score VTE risk assessment model has not been validated in patients with uterine cancer.
•
Patients with uterine cancer undergoing chemotherapy had a VTE rate of 6.5%.
•
Uterine cancer patients that had a VTE during treatment had a non-statistically significant higher average Khorana score.
•
A high Khorana score is a poor predictor of VTE in patients with uterine cancer undergoing chemotherapy.
Details
- Title: Subtitle
- Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer
- Creators
- Rachael N. Piver - The Ohio State University Wexner Medical CenterVincent M. Wagner - The Ohio State UniversityMonica D. Levine - The Ohio State UniversityFloor J. Backes - The Ohio State UniversityLaura J. Chambers - The Ohio State UniversityDavid E. Cohn - The Ohio State UniversityLarry J. Copeland - The Ohio State UniversityCasey M. Cosgrove - The Ohio State UniversityChrista I. Nagel - The Ohio State UniversityDavid M. O'Malley - The Ohio State UniversityKristin L. Bixel - The Ohio State University
- Resource Type
- Journal article
- Publication Details
- Gynecologic oncology reports, Vol.46, pp.101156-101156
- DOI
- 10.1016/j.gore.2023.101156
- PMID
- 36910448
- PMCID
- PMC9995928
- NLM abbreviation
- Gynecol Oncol Rep
- ISSN
- 2352-5789
- eISSN
- 2352-5789
- Publisher
- Elsevier
- Language
- English
- Date published
- 04/01/2023
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9984459619802771
Metrics
7 Record Views